ES2121071T3 - Compuestos de oxazolidina y su empleo como medicamentos. - Google Patents

Compuestos de oxazolidina y su empleo como medicamentos.

Info

Publication number
ES2121071T3
ES2121071T3 ES93810598T ES93810598T ES2121071T3 ES 2121071 T3 ES2121071 T3 ES 2121071T3 ES 93810598 T ES93810598 T ES 93810598T ES 93810598 T ES93810598 T ES 93810598T ES 2121071 T3 ES2121071 T3 ES 2121071T3
Authority
ES
Spain
Prior art keywords
compounds
medicines
oxazolidine compounds
denote
adrenoreceptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93810598T
Other languages
English (en)
Inventor
Alfred Dr Sallmann
Hans-Peter Dr Gschwind
Eric Dr Francotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2121071T3 publication Critical patent/ES2121071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS COMPUESTOS OXAZOLIDINAS DE FORMULA (I), DONDE R1 Y R2 SIMULTANEAMENTE HIDROGENO, O AMBOS RESTOS ALQUILO DE BAJO NUMERO DE CARBONOS IGUALES O CONJUNTAMENTE ALQUILOS DE BAJO NUMERO DE CARBONOS DE 4 A 7 MIEMBROS Y SUS SALES EN FORMA RACEMICA QUIRAL, PROCEDIMIENTO PARA LA PRODUCCION DE LOS COMPUESTOS MENCIONADOS, PREPARADOS FARMACEUTICOS CONTENIENDO ESTOS COMPUESTOS Y SU APLICACION COMO SUSTANCIAS ACTIVAS EN MEDICAMENTOS. LOS COMPUESTOS TIENEN UNA ACCION ESTIMULANTE SOBRE BETA-ADRENORECEPTORES Y PUEDEN EMPLEARSE EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON OBSTRUCCIONES REVERSIBLES DE LAS VIAS RESPIRATORIAS COMO ASMA Y BRONQUITIS CRONICA Y ADEMAS EMPLEARSE PARA GENESIS INFLAMATORIAS DIFERENTES.
ES93810598T 1992-09-02 1993-08-24 Compuestos de oxazolidina y su empleo como medicamentos. Expired - Lifetime ES2121071T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH274292 1992-09-02

Publications (1)

Publication Number Publication Date
ES2121071T3 true ES2121071T3 (es) 1998-11-16

Family

ID=4240593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93810598T Expired - Lifetime ES2121071T3 (es) 1992-09-02 1993-08-24 Compuestos de oxazolidina y su empleo como medicamentos.

Country Status (14)

Country Link
US (1) US5369117A (es)
EP (1) EP0586344B1 (es)
JP (1) JP3070812B2 (es)
KR (1) KR100306652B1 (es)
AT (1) ATE170848T1 (es)
AU (1) AU672984B2 (es)
CA (1) CA2105215C (es)
DE (1) DE59308970D1 (es)
DK (1) DK0586344T3 (es)
ES (1) ES2121071T3 (es)
IL (1) IL106862A (es)
NZ (1) NZ248550A (es)
TW (1) TW223065B (es)
ZA (1) ZA936393B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048857A (en) * 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
CA2163399A1 (en) * 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
DE2366625C2 (es) * 1972-02-05 1988-06-09 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp
US4219655A (en) * 1979-07-16 1980-08-26 Stauffer Chemical Company Process for the production of N-acyl substituted oxazolidines
US4407819A (en) * 1980-08-25 1983-10-04 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for the depression of fat deposition in warm blooded animals
US4705798A (en) * 1985-09-27 1987-11-10 University Of Iowa Research Foundation Phenylephrine prodrug useful as mydriatic agent
US5066793A (en) * 1987-10-26 1991-11-19 Ciba-Geigy Corporation Finely particulate cellulose esters of aromatic or aromatic-aliphatic carboxylic acids, process for their preparation, and the use thereof

Also Published As

Publication number Publication date
JPH06157487A (ja) 1994-06-03
NZ248550A (en) 1995-09-26
CA2105215A1 (en) 1994-03-03
JP3070812B2 (ja) 2000-07-31
ZA936393B (en) 1994-03-25
DK0586344T3 (da) 1999-06-07
KR940007010A (ko) 1994-04-26
EP0586344B1 (de) 1998-09-09
TW223065B (es) 1994-05-01
CA2105215C (en) 2004-06-29
AU4499393A (en) 1994-03-10
US5369117A (en) 1994-11-29
IL106862A0 (en) 1993-12-28
DE59308970D1 (de) 1998-10-15
ATE170848T1 (de) 1998-09-15
IL106862A (en) 1997-07-13
EP0586344A1 (de) 1994-03-09
KR100306652B1 (ko) 2001-12-28
AU672984B2 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
TW330202B (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
AU557691B2 (en) 2-penem antibiotics and their oxa-aza-, and carba analogues
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
FR2581063B1 (fr) Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
NO873722L (no) Nye derivater av 4,5-dihydro-oksazoler, samt fremgangsmaate for deres fremstilling.
ES2121071T3 (es) Compuestos de oxazolidina y su empleo como medicamentos.
DK624989A (da) Makrolidforbindelser
DK0457883T3 (da) Nye bicycliske aminosubstituerede forbindelser
FR2597097B1 (fr) Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique
ATE74138T1 (de) Heptanoyl-glu-asp-ala-amino-saeureimmunstimulanten.
DK0446921T3 (da) Optisk aktive alkylendioxybenzenderivater og deres anvendelse ved terapi
ATE9584T1 (de) Antibakterielle beta-lactam-verbindungen, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
DK0500905T3 (da) Farmaceutiske midler til brug ved behandling af AIDS
NO178302C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte 3-tia- henholdsvis 3-oksa-alkylflavoner, samt mellomprodukter for fremgangsmåten
ES2121621T3 (es) Derivados de acido n,n'-bis(2-hidroxibencil)etilendiamino-n,n'-diacetico como agentes quelantes.
TH13838EX (th) สิ่งเคลือบบนกระจก

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 586344

Country of ref document: ES